Abstract
The ability to introduce genes of neurotrophic factors into eukaryotic cells provides a novel way to study neurobiological processes in vitro and in vivo (1–6). To study the functional role of the growth factors in vivo, genetically modified cells expressing neurotrophin have been grafted in the central nervous system (CNS) (2,3,6). In different animal models of CNS degenerative diseases, neurotrophic factors secreted from grafted cells can prevent neuronal degeneration and promote functional recovery after injury (1–11). The neurotrophin family is comprised of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5) (12–14). Although structurally similar, they differ in their regional and temporal distribution, receptor specificity, and biological activity. NGF, the first prototypic neurotrophin, is synthesized as part of a large precursor protein within which mature, bioactive NGF occupies the C-terminal half, and the N-terminal half contains a signal peptide (18 amino acid) preceding a large pro region. The pro sequence in combination with the signal (pre) sequence is necessary for the secretion of correctly processed, biologically active NGF (15). All neurotrophins show considerable structural homology to NGF and contain similar signal peptide and pro sequences.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ray, J., Fisher, L. J., and Gage, F. H. (1994) Implantation of genetically modified cells in the brain, in Somatic Gene Therapy (Chang, P. L., ed.), CRC, Boca Raton, FL, pp. 161–182.
Fisher, L. J. (1995) Engineered cells: a promising therapeutic approach for neural disease. Res. Neurol. Neurosci. 8, 49–57.
Blümer, U., Naldini, L., Verma, I. M., Trono, D., and Gage, F. H. (1996) Applications of gene therapy to the CNS. Hum. Mol. Genet. 5, 1397–1404.
Verma, I. M. and Somia, N. (1997) Gene therapy—promises, problems and prospects. Nature 389, 239–242.
Senut, M.-C., Aubert, I., Horner, P. J., and Gage, F. H. (1998) Gene transfer for adult CNS regeneration and aging, in Gene Therapy for Neurological Disorders and Brain Tumors (Chiocca, E. A. and Breakfield, X. O., eds.), Humana, Totowa, NJ, pp. 345–375.
Blesch, A. and Tuszynski, M. H. (1995) Ex vivo gene therapy for Alzheimer’s disease and spinal cord injury. Clin. Neurosci. 3, 268–274.
Rosenberg, M. B., Friedmann, T., Robertson, R. R., Tuszynski, M., Wolff, J. J., Breakfield, X. O., et al. (1988) Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science 242, 1575–1578.
Tuszynski, M. H., Senut, M.-C., Ray, J., and Roberts, J. (1994) Somatic gene transfer to the adult primate central nervous system: in vitro and in vivo characterization of cells genetically modified to secret nerve growth factor. Neurobiol. Dis. 1, 67–78.
Chen, K. S. and Gage, F. H. (1995) Somatic gene transfer of NGF to the aged brain: behavioral and morphological amelioration. J. Neurosci. 15, 2819–2825.
Lucidi-Phillipi, C. A., Gage, F. H., Shults, C. W., Jones, K. R., Reichardt, L. F.,and Kang, U. J. (1995) Brain-derived neurotrophic factor-transduced fibroblasts: production of BDNF and effects of grafting to the adult brain. J. Comp. Neurol. 354, 361–376.
Senut, M.-C., Tuszynski, M. H., Raymon, H. K., Suhr, S. T., Liou, N. H., Jones, K. R., et al. (1995) Regional differences in responsiveness of adult CNS axons to grafts of cells expressing human neurotrophin 3. Exp. Neurol. 135, 36–55.
Bothwell, M. (1995) Functional interactions of neurotrophins and neurotrophin receptors. Ann. Rev. Neurosci. 18, 223–253.
Ibanez, C. F. (1995) Neurotrophic factors: from structure-function to designing effective therapeutics. TIBTECH 13, 217–227.
Ip, N. Y. and Yancopoulos, G. D. (1996) The neurotrophins and CNTF: two families of collaborative neurotrophic factors. Ann. Rev. Neurosci. 19, 491–515.
Suter, U., Heymach, J. V., and Shooter, E. M. (1991) Two conserved domains in the NGF propeptide are necessary and sufficient of correctly processed and biologically active NGF. EM BO J. 10, 256–263.
Suhr, S. T. and Gage, F. H. (1993) Gene therapy for neurological disease. Arch. Neurol. 50, 1252–1268.
Palmer, T. D. and Gage, F. H. (1996) Delivery of gene products to the central nervous system by grafting retrovirally engineered neuronal and non-neuronal cells, inProtocols for Gene Transfer in Neuroscience (Lowenstein, P. R. and Enquist, L. W., eds.), Wiley, New York, pp. 235–262.
Reeves, S. A. (1998) Retrovirus vectors and regulatable promoters, in Gene Therapy for Neurological Disorders and Brain Tumors (Chiocca, E. A. and Breakfield, X. O., eds.) Humana, Totowa, NJ, pp. 7–38.
Braas, G., Searle, P. F., Slater, N. K., and Lyddiatt, A. (1996) Strategies for the isolation and purification of retroviral vectors for gene therapy. Biosep. 6, 211–228.
Ray, J. and Gage, F. H. (1992) Gene transfer into established and primary fibroblast cell lines: comparison of transfection methods and promoters. BioTechniques 1, 598–603.
Chen, C. and Okayama, H. (1988) Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. BioTechniques 66, 32–38.
Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., et al. (1987) Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA 84, 7413–7417.
Andreason, G. L. and Evans, G. A. (1989) Optimization of electroporation for transfection of mammalian cell lines. Anal. Biochem. 180, 269–275.
Cappechi, M. R. (1980) High-efficiency transformation by direct microinjection of DNA into cultured cells. Cell 22, 479–488.
Miller, A. D. and Rosman, G. J. (1989) Improved retroviral vectors for gene transfer and expression. BioTechniques 7, 980–982.
Hoshimaru, M., Ray, J., Sah, D. W. Y., and Gage, F H. (1996) Differentiation of immortalized adult neuronal progenitor cell line HC2S2 into neurons by regulatable suppression of v-myc oncogene. Proc. Natl. Acad. Sci. USA. 93, 1518–1523.
Paulus, W., Baur, I., Boyce, F. M., Breakfield, X. O., and Reeves, S A. (1996) Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. J. Virol. 70, 62–67.
Mann, R., Mulligan, R. C., and Baltimore, D. (1983) Construction of a retroviral packaging mutant and its use to produce helper-free defective retrovirus. Cell 33, 153–159.
Pear, W. S., Nolan, G. P., Scott, M. L., and Baltimore, D. (1993) Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90, 8392–8396.
Sambrook, J., Fritch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual (Nolan, C., ed.), Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
Blümer, U., Naldini, L., Kafri, T., Trono, D., Verma, I. M., and Gage, F. H. (1997) Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J. Virol. 71, 6641–6649.
Erlich, H. A. (1992) PCR Technology: Principles and Applications for DNA Amplification. W. H. Freeman, New York.
Green, L. A. and Rukenstein, A. (1989) The quantitative bioassay of nerve growth factor with PC 12 cells, in Nerve Growth Factor (Rush, R. A., eds.), IBRO Handbook Series: Methods in the Neureosciences, Wiley, New York, pp. 139–147.
Davies, A. M. (1989) Neurotrophic factor bioassay using dissociated neurons, in Nerve Growth Factor (Rush, R. A., eds.), IBRO Handbook Series: Methods in the Neureosciences, Wiley, New York, pp. 95–109.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Humana Press Inc.
About this protocol
Cite this protocol
Ray, J., Gage, F.H. (2001). Construction of Cells Expressing Neurotrophins. In: Rush, R.A. (eds) Neurotrophin Protocols. Methods in Molecular Biology™, vol 169. Humana Press. https://doi.org/10.1385/1-59259-060-8:115
Download citation
DOI: https://doi.org/10.1385/1-59259-060-8:115
Publisher Name: Humana Press
Print ISBN: 978-0-89603-699-4
Online ISBN: 978-1-59259-060-5
eBook Packages: Springer Protocols